Events

Virtual Cybersecurity B2B Meetings & Webinar
MAY
Mon
19
MAY
Tue
20
MAY
Wed
21

This was 10 months ago

Location

Online

Programmes
Civil Security Cybersecurity

The Enterprise Europe Network and SeREN5, the HorizonEurope NCPs Network for Cluster 3 research Civil Security for Society organise a twofold Virtual Cybersecurity B2B event

The event consists of

  • a fully virtual B2B event where participants can profile their offers and requests of collaboration, first ideas to set-up consortia and good proposals, with the help of both Enterprise Europe Network and Horizon Europe Cluster 3 NCPs
  • a hands-on, awareness-raising webinar on the forthcoming calls on topics related to the cybersecurity (Destination - Increased Cybersecurity) by SeREN5 network representative (19 May 2025, 10.00-12.00).

Participation is free of charge, but mandatory via this link.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.